{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:20:08Z","timestamp":1789708808300,"version":"4.0.1"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ECCO Pioneer award"},{"name":"NWO Veni"},{"name":"FIBROTARGET","award":["101080523"],"award-info":[{"award-number":["101080523"]}]},{"name":"ECCO Pioneer Award."},{"name":"FWO-Research Foundation \u2013 Flanders","award":["11PF324N"],"award-info":[{"award-number":["11PF324N"]}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202206170019"],"award-info":[{"award-number":["202206170019"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intestinal fibrosis in inflammatory bowel disease (IBD) is caused by uncontrolled accumulation of extracellular matrix deposited by fibroblasts. This may result in stricture formation, especially in Crohn\u2019s disease. Since there are no anti-fibrotic drugs available, endoscopic or surgical interventions are the only options to treat intestinal strictures. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway plays a crucial role in intestinal homeostasis and inflammation. JAK inhibition represents a relatively novel therapeutic strategy in IBD by simultaneously blocking multiple cytokines across various inflammatory pathways. Interestingly, JAK inhibitors extend their benefits beyond anti-inflammatory effects, as they have been shown to interfere with fibrotic processes in various diseases, including IBD. We here summarize the current understanding of the role of the JAK-STAT pathway in the pathogenesis of intestinal fibrosis and the application of JAK inhibitors for IBD. In addition, we discuss the use of JAK inhibitors in other fibrotic-related diseases to postulate how these agents might be applied for future treatment of intestinal fibrosis.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjaf087","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T13:59:23Z","timestamp":1748095163000},"source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease"],"prefix":"10.1093","volume":"19","author":[{"given":"Jie","family":"Su","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia A","family":"Lartey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Amsterdam UMC, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Zanella","sequence":"additional","affiliation":[{"name":"Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas J A C","family":"Hawinkels","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Matteoli","sequence":"additional","affiliation":[{"name":"Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology , Amsterdam UMC, Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5298-1117","authenticated-orcid":false,"given":"Marieke C","family":"Barnhoorn","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"2025063009413238500_CIT0001","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ibd\/izz075","article-title":"Challenges in IBD research: preclinical human IBD mechanisms","volume":"25","author":"Pizarro","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413238500_CIT0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.trsl.2019.03.005","article-title":"Pathogenesis of fibrostenosing Crohn\u2019s disease","volume":"209","author":"Li","year":"2019","journal-title":"Transl Res."},{"key":"2025063009413238500_CIT0003","doi-asserted-by":"crossref","first-page":"e00082","DOI":"10.14309\/ctg.0000000000000082","article-title":"Fibrosis mediators in the colonic mucosa of acute and healed ulcerative colitis","volume":"10","author":"Gundersen","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"2025063009413238500_CIT0004","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5217\/ir.2019.09148","article-title":"Fibrostenotic strictures in Crohn\u2019s disease","volume":"18","author":"Yoo","year":"2020","journal-title":"Intest Res."},{"key":"2025063009413238500_CIT0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41575-024-00935-y","article-title":"A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn\u2019s disease in clinical practice","volume":"21","author":"Bettenworth","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025063009413238500_CIT0006","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/biomedicines13040775","article-title":"FAPi PET\/CT imaging to identify fibrosis in immune-mediated inflammatory diseases","volume":"13","author":"Lartey","year":"2025","journal-title":"Biomedicines."},{"key":"2025063009413238500_CIT0007","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity."},{"key":"2025063009413238500_CIT0008","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol."},{"key":"2025063009413238500_CIT0009","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity."},{"key":"2025063009413238500_CIT0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol."},{"key":"2025063009413238500_CIT0011","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2025063009413238500_CIT0012","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/emboj\/21.7.1754","article-title":"Regulated nuclear import of the STAT1 transcription factor by direct binding of importin-alpha","volume":"21","author":"McBride","year":"2002","journal-title":"EMBO J."},{"key":"2025063009413238500_CIT0013","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stemcr.2017.11.015","article-title":"JAK\/STAT-1 signaling is required for reserve intestinal stem cell activation during intestinal regeneration following acute inflammation","volume":"10","author":"Richmond","year":"2018","journal-title":"Stem Cell Rep."},{"key":"2025063009413238500_CIT0014","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.stemcr.2024.06.006","article-title":"JAK\/STAT signaling promotes the emergence of unique cell states in ulcerative colitis","volume":"19","author":"Maciag","year":"2024","journal-title":"Stem Cell Rep."},{"key":"2025063009413238500_CIT0015","doi-asserted-by":"crossref","first-page":"1447608","DOI":"10.3389\/fimmu.2024.1447608","article-title":"Neutrophil-fibroblast crosstalk drives immunofibrosis in Crohn\u2019s disease through IFNalpha pathway","volume":"15","author":"Gavriilidis","year":"2024","journal-title":"Front Immunol."},{"key":"2025063009413238500_CIT0016","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2468-1253(19)30414-5","article-title":"Small molecule oral targeted therapies in ulcerative colitis","volume":"5","author":"Shivaji","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025063009413238500_CIT0017","doi-asserted-by":"crossref","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","article-title":"JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases","volume":"10","author":"Herrera-deGuise","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"2025063009413238500_CIT0018","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"2025063009413238500_CIT0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/biom13010119","article-title":"The Role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms","volume":"13","author":"Liu","year":"2023","journal-title":"Biomolecules."},{"key":"2025063009413238500_CIT0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12967-022-03366-y","article-title":"Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1\/2","volume":"20","author":"Song","year":"2022","journal-title":"J Transl Med."},{"key":"2025063009413238500_CIT0021","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/gutjnl-2022-328608","article-title":"Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis","volume":"73","author":"Lin","year":"2024","journal-title":"Gut."},{"key":"2025063009413238500_CIT0022","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell."},{"key":"2025063009413238500_CIT0023","doi-asserted-by":"crossref","first-page":"e173835","DOI":"10.1172\/JCI173835","article-title":"Intercellular interaction between FAP+ fibroblasts and CD150+ inflammatory monocytes mediates fibrostenosis in Crohn\u2019s disease","volume":"134","author":"Ke","year":"2024","journal-title":"J Clin Invest."},{"key":"2025063009413238500_CIT0024","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1053\/j.gastro.2023.07.014","article-title":"Stricturing Crohn\u2019s disease single-cell RNA sequencing reveals fibroblast heterogeneity and intercellular interactions","volume":"165","author":"Mukherjee","year":"2023","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izae292","article-title":"New insights into the pathogenesis of intestinal fibrosis in inflammatory bowel diseases: focusing on intestinal smooth muscle cells","volume":"31","author":"Kalafateli","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413238500_CIT0026","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in IBD: from pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut."},{"key":"2025063009413238500_CIT0027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer."},{"key":"2025063009413238500_CIT0028","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41590-024-01804-1","article-title":"JAK-STAT signaling maintains homeostasis in T cells and macrophages","volume":"25","author":"Fortelny","year":"2024","journal-title":"Nat Immunol."},{"key":"2025063009413238500_CIT0029","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/intimm\/dxf031","article-title":"The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3(-\/-) and IL-2 receptor gamma(-\/-) mice","volume":"14","author":"Murata","year":"2002","journal-title":"Int Immunol."},{"key":"2025063009413238500_CIT0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2016.02.010","article-title":"The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses","volume":"29","author":"Blaszczyk","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"2025063009413238500_CIT0031","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.immuni.2012.01.011","article-title":"Constitutive type I interferon modulates homeostatic balance through tonic signaling","volume":"36","author":"Gough","year":"2012","journal-title":"Immunity."},{"key":"2025063009413238500_CIT0032","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct Target Ther."},{"key":"2025063009413238500_CIT0033","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"2025063009413238500_CIT0034","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.3748\/wjg.v26.i28.4055","article-title":"Differential regulation of JAK\/STAT-signaling in patients with ulcerative colitis and Crohn\u2019s disease","volume":"26","author":"Cordes","year":"2020","journal-title":"World J Gastroenterol."},{"key":"2025063009413238500_CIT0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2025063009413238500_CIT0036","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/emmm.201100192","article-title":"Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation","volume":"4","author":"Gilbert","year":"2012","journal-title":"EMBO Mol Med."},{"key":"2025063009413238500_CIT0037","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MIB.0b013e31828028ad","article-title":"Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice","volume":"19","author":"Willson","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413238500_CIT0038","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/jcm14020608","article-title":"The cell-specific effects of JAK1 inhibitors in ulcerative colitis","volume":"14","author":"Veltkamp","year":"2025","journal-title":"J Clin Med."},{"key":"2025063009413238500_CIT0039","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn\u2019s disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res."},{"key":"2025063009413238500_CIT0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MPG.0b013e318246be78","article-title":"STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease","volume":"55","author":"Willson","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2025063009413238500_CIT0041","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/gutjnl-2011-300777","article-title":"Genetic factors conferring an increased susceptibility to develop Crohn\u2019s disease also influence disease phenotype: results from the IBDchip European Project","volume":"62","author":"Cleynen","year":"2013","journal-title":"Gut."},{"key":"2025063009413238500_CIT0042","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"2025063009413238500_CIT0043","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-beta (TGF-beta) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J Biol Chem."},{"key":"2025063009413238500_CIT0044","doi-asserted-by":"crossref","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front Bioeng Biotechnol."},{"key":"2025063009413238500_CIT0045","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","article-title":"Noncanonical STAT3 activation regulates excess TGF-beta1 and collagen I expression in muscle of stricturing Crohn\u2019s disease","volume":"194","author":"Li","year":"2015","journal-title":"J Immunol."},{"key":"2025063009413238500_CIT0046","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun."},{"key":"2025063009413238500_CIT0047","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1053\/j.gastro.2008.08.055","article-title":"IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis","volume":"135","author":"Fichtner-Feigl","year":"2008","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0048","doi-asserted-by":"crossref","first-page":"e179472","DOI":"10.1172\/JCI179472","article-title":"TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn\u2019s disease","volume":"134","author":"Zhang","year":"2024","journal-title":"J Clin Invest."},{"key":"2025063009413238500_CIT0049","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2013.04.024","article-title":"STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion","volume":"336","author":"Cho","year":"2013","journal-title":"Cancer Lett."},{"key":"2025063009413238500_CIT0050","doi-asserted-by":"crossref","first-page":"14665","DOI":"10.1074\/jbc.M707429200","article-title":"Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function","volume":"283","author":"Cheng","year":"2008","journal-title":"J Biol Chem."},{"key":"2025063009413238500_CIT0051","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/s41467-021-22450-3","article-title":"Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer","volume":"12","author":"Nishina","year":"2021","journal-title":"Nat Commun."},{"key":"2025063009413238500_CIT0052","article-title":"Understanding the mechanisms underlying the lack of response to Janus kinase inhibition in ulcerative colitis","author":"Mel\u00f3n-Ardanaz","year":"2025","journal-title":"J Crohns Colitis."},{"key":"2025063009413238500_CIT0053","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.gastro.2022.09.006","article-title":"Th17 cell-derived amphiregulin promotes colitis-associated intestinal fibrosis through activation of mTOR and MEK in intestinal myofibroblasts","volume":"164","author":"Zhao","year":"2023","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0054","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol."},{"key":"2025063009413238500_CIT0055","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med."},{"key":"2025063009413238500_CIT0056","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"2025063009413238500_CIT0057","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin Cancer Res."},{"key":"2025063009413238500_CIT0058","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"key":"2025063009413238500_CIT0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature13383","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"512","author":"Arranz","year":"2014","journal-title":"Nature."},{"key":"2025063009413238500_CIT0060","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"key":"2025063009413238500_CIT0061","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol."},{"key":"2025063009413238500_CIT0062","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood."},{"key":"2025063009413238500_CIT0063","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.clml.2017.08.002","article-title":"The treatment landscape of myelofibrosis before and after ruxolitinib approval","volume":"17","author":"Kuykendall","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2025063009413238500_CIT0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia."},{"key":"2025063009413238500_CIT0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J Hematol Oncol."},{"key":"2025063009413238500_CIT0066","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N Engl J Med."},{"key":"2025063009413238500_CIT0067","doi-asserted-by":"crossref","first-page":"684699","DOI":"10.3389\/fimmu.2021.684699","article-title":"Interstitial lung disease in connective tissue disease: a common lesion with heterogeneous mechanisms and treatment considerations","volume":"12","author":"Shao","year":"2021","journal-title":"Front Immunol."},{"key":"2025063009413238500_CIT0068","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1183\/09031936.00069307","article-title":"Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms","volume":"30","author":"Maher","year":"2007","journal-title":"Eur Respir J."},{"key":"2025063009413238500_CIT0069","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int J Mol Sci ."},{"key":"2025063009413238500_CIT0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","article-title":"The JAK2 pathway is activated in idiopathic pulmonary fibrosis","volume":"19","author":"Milara","year":"2018","journal-title":"Respir Res."},{"key":"2025063009413238500_CIT0071","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2020","journal-title":"J Scleroderma Relat Disord."},{"key":"2025063009413238500_CIT0072","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1096\/fj.15-273953","article-title":"STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation","volume":"30","author":"Pedroza","year":"2016","journal-title":"FASEB J."},{"key":"2025063009413238500_CIT0073","doi-asserted-by":"crossref","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"2025063009413238500_CIT0074","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice","volume":"21","author":"Sendo","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"2025063009413238500_CIT0075","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"2025063009413238500_CIT0076","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"key":"2025063009413238500_CIT0077","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"2025063009413238500_CIT0078","doi-asserted-by":"crossref","first-page":"108273","DOI":"10.1016\/j.clim.2019.108273","article-title":"Baricitinib experience on STING-associated vasculopathy with onset in infancy: a representative case from Turkey","volume":"212","author":"Balci","year":"2020","journal-title":"Clin Immunol."},{"key":"2025063009413238500_CIT0079","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","volume":"81","author":"Bader-Meunier","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"2025063009413238500_CIT0080","doi-asserted-by":"crossref","first-page":"106748","DOI":"10.1016\/j.intimp.2020.106748","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d\u2019Alessandro","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"2025063009413238500_CIT0081","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology."},{"key":"2025063009413238500_CIT0082","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fphys.2012.00069","article-title":"Cytokines and STATs in liver fibrosis","volume":"3","author":"Kong","year":"2012","journal-title":"Front Physiol."},{"key":"2025063009413238500_CIT0083","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0084","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest."},{"key":"2025063009413238500_CIT0085","first-page":"92","article-title":"Cytokines, STATs and liver disease","volume":"2","author":"Gao","year":"2005","journal-title":"Cell Mol Immunol."},{"key":"2025063009413238500_CIT0086","doi-asserted-by":"crossref","first-page":"44910","DOI":"10.1038\/srep44910","article-title":"Quantitative proteomic analysis on activated hepatic stellate cells reversion reveal STAT1 as a key regulator between liver fibrosis and recovery","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep."},{"key":"2025063009413238500_CIT0087","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.21419","article-title":"STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity","volume":"44","author":"Jeong","year":"2006","journal-title":"Hepatology."},{"key":"2025063009413238500_CIT0088","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1053\/j.gastro.2010.02.049","article-title":"Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis","volume":"138","author":"Mair","year":"2010","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0089","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.2353\/ajpath.2010.090469","article-title":"Lack of glycoprotein 130\/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis","volume":"176","author":"Plum","year":"2010","journal-title":"Am J Pathol."},{"key":"2025063009413238500_CIT0090","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/sj.onc.1209281","article-title":"Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production","volume":"25","author":"Ogata","year":"2006","journal-title":"Oncogene."},{"key":"2025063009413238500_CIT0091","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41374-018-0127-3","article-title":"The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis","volume":"98","author":"Wang","year":"2018","journal-title":"Lab Invest."},{"key":"2025063009413238500_CIT0092","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.32746","article-title":"Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis","volume":"77","author":"Torres","year":"2023","journal-title":"Hepatology."},{"key":"2025063009413238500_CIT0093","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune\u2011mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol Med Rep."},{"key":"2025063009413238500_CIT0094","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025063009413238500_CIT0095","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"key":"2025063009413238500_CIT0096","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2025063009413238500_CIT0097","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.30171","article-title":"Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis","volume":"63","author":"Avouac","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2025063009413238500_CIT0098","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/rheumatology\/kex347","article-title":"Role of STAT3 in skin fibrosis and transforming growth factor beta signalling","volume":"57","author":"Pedroza","year":"2018","journal-title":"Rheumatology (Oxford)."},{"key":"2025063009413238500_CIT0099","doi-asserted-by":"crossref","first-page":"109723","DOI":"10.1016\/j.intimp.2023.109723","article-title":"Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis","volume":"116","author":"Bellamri","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"2025063009413238500_CIT0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jdermsci.2020.12.007","article-title":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","volume":"101","author":"Aung","year":"2021","journal-title":"J Dermatol Sci."},{"key":"2025063009413238500_CIT0101","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1038\/s41598-022-06581-1","article-title":"Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis","volume":"12","author":"Karatas","year":"2022","journal-title":"Sci Rep."},{"key":"2025063009413238500_CIT0102","doi-asserted-by":"crossref","first-page":"859330","DOI":"10.3389\/fmed.2022.859330","article-title":"JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","volume":"9","author":"Hou","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025063009413238500_CIT0103","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2025063009413238500_CIT0104","first-page":"5293981","article-title":"Fifty-two-week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease-modifying antirheumatic drug therapy that was successfully treated with baricitinib: a novel case report","volume":"2019","author":"Fujita","year":"2019","journal-title":"Case Rep Rheumatol."},{"key":"2025063009413238500_CIT0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/03009742.2017.1387673","article-title":"Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis","volume":"47","author":"Komai","year":"2018","journal-title":"Scand J Rheumatol."},{"key":"2025063009413238500_CIT0106","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s10067-023-06660-2","article-title":"Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease","volume":"42","author":"Junfei","year":"2023","journal-title":"Clin Rheumatol."},{"key":"2025063009413238500_CIT0107","doi-asserted-by":"crossref","first-page":"e159566","DOI":"10.1172\/jci.insight.159566","article-title":"Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial","volume":"7","author":"Khanna","year":"2022","journal-title":"JCI Insight."},{"key":"2025063009413238500_CIT0108","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"2025063009413238500_CIT0109","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/ibd\/izab116","article-title":"Randomized controlled trial substudy of cell-specific mechanisms of janus kinase 1 inhibition with upadacitinib in the Crohn\u2019s disease intestinal mucosa: analysis from the CELEST study","volume":"27","author":"Aguilar","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413238500_CIT0110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ibd\/izac246","article-title":"The clinical response of upadacitinib and risankizumab is associated with reduced inflammatory bowel disease anti-TNF-alpha inadequate response mechanisms","volume":"29","author":"Wang","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025063009413238500_CIT0111","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-021-03549-5","article-title":"Cross-tissue organization of the fibroblast lineage","volume":"593","author":"Buechler","year":"2021","journal-title":"Nature."},{"key":"2025063009413238500_CIT0112","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1681\/ASN.2014070717","article-title":"JAK3\/STAT6 stimulates bone marrow-derived fibroblast activation in renal fibrosis","volume":"26","author":"Yan","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"2025063009413238500_CIT0113","doi-asserted-by":"crossref","first-page":"i1111","DOI":"10.1093\/ecco-jcc\/jjad212.0702","article-title":"P572 Evaluation of safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis: a phase Ib\/IIa, randomized, double blind, placebo controlled clinical trial","volume":"18","author":"Barreiro-de Acosta","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025063009413238500_CIT0114","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs."},{"key":"2025063009413238500_CIT0115","first-page":"6","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC Study","volume":"18","author":"Danese","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2025063009413238500_CIT0116","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem."},{"key":"2025063009413238500_CIT0117","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol."},{"key":"2025063009413238500_CIT0118","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025063009413238500_CIT0119","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2024.09.073","article-title":"A phase 2a trial of brepocitinib for cicatricial alopecia","volume":"92","author":"David","year":"2025","journal-title":"J Am Acad Dermatol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf087\/63328807\/jjaf087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf087\/63328807\/jjaf087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/6\/jjaf087\/63328807\/jjaf087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:41:56Z","timestamp":1751290916000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf087\/8145528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf087","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,24]]},"article-number":"jjaf087"}}